PTPσ Inhibitor, ISP

A cell-permeable, TAT conjugated peptide derived from the protein tyrosine phosphatase sigma (PTPsigma) wedge domain that binds to PTPsigma and relieves glial-derived chondroitin sulfate proteoglycan (CSPG)-mediated inhibition. Shown to cross the blood-brain barrier. Does not bind to other CSPG receptors, such as LAR and NgRs. By blocking the PTPsigma-CSPG interaction it abolishes CSPG -mediated inhibition of axonal regrowth and sprouting. Shown to promote adult sensory neuron growth cone (~ 2.5 µM). Restores serotonergic innervations to the spinal cord below the level of injury and promotes progressive functional recovery of both locomotor and urinary systems after spinal cord injury in a rat model (11 µg/day).

Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.

Cell permeable: yes

Primary Target
PTPσ

Reversible: yes

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Lang, B. T, et al. 2015. Nature.518, 404.

NH2-GRKKRRQRRRCDMAEHMERLKANDSLKLSQEYESI-NH2

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)